When Healing Time Matters, Neox® Has You Covered!

We are in a race against time to heal chronic wounds.

BioTissue Surgical products provide the natural healing properties of human birth tissue to the wound.

When treating patients with comorbidities, every moment counts.

The Neox® line of human amniotic membrane allografts are adjunct treatment modalities that help support regenerative healing for a variety of wounds ranging from common surgical wounds to complex chronic diabetic foot ulcers, acute, partial, and full-thickness wounds.1-3,6,7

• High closure rate2,6,7

• Few applications2,6,7

• Low cost of care1

• Expedited healing

The BioTissue Difference –

Through Thick & Thin

Type 2 Diabetes & Septic
  • Type 2 Diabetes & Septic
  • Non-Healing Venous Ulcer
  • Necrotizing Fasciitis
  • Type 2 Diabetes & Septic
  • Non-Healing Venous Ulcer
  • Necrotizing Fasciitis

Type 2 Diabetes & Septic Wound with Exposed Tendons

  • 48-year-old female with Type 2 Diabetes and a septic wound with exposed tendons (FIG. 1).
  • Patient received multiple recommendations for amputation.
  • Following debridement and placement of Neox 1K (FIG. 2 and FIG. 3), complete wound closure was attained in 3-months (FIG. 4).

Aziz Rasooli, DPM, MS, AACFAS – Los Angeles Bone and Joint Orthopedic Institute, Los Angeles, CA

Non-Healing Venous Ulcer

A 70-year-old wheelchair/bed bound male with a 50 pack/year history of cigarette abuse, combinatorial venous & diabetes disease, Peripheral Vascular Disease (PVD), and joint contracture presented with a 2-year non-healing Venous Leg Ulcer (VLU), & Diabetic Foot Ulcer (DFU) on the medial right ankle despite peripheral bypass surgery.

The patient refused smoking cessation, and failed local wound care and antibiotic therapy.

Wayne Caputo, DPM, FACFAS – Clara Maass Medical Center, Newark, NJ

Necrotizing Fasciitis

  • 65-year-old-male with DM, CAD, PAD, with WBC of 15.4 and A1c of 8.3.
  • Right leg ulcer failed debridement by outside physician.

Lawrence Chen, DPM – Foot and Ankle Medical Group, San Jose, CA

Download Our Wound Case Studies & Product Brochure

Explore the utilization of human birth tissue in the treatment of both acute and chronic wounds.

By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.

Advanced Wound Care Products

01

Cryopreserved, ultra-thick human amniotic membrane allograft used as an adjunct treatment for chronic, acute, partial, and full-thickness wounds.

02

Cryopreserved amniotic membrane allograft for wound applications, a thinner alternative to Neox 1K. The allograft is delivered on a non-implantable, gridded paper backing for easier handling and application.

03

A hydrated, room temperature, ultra-thick human amniotic membrane allograft derived from umbilical cord.

Pioneers of Regenerative

Wound Healing

Our extensive clinical research experience is the foundation of our commitment to optimize patient outcomes.

38+ Years

Research & Development

800,000+

Human Clinical Applications

390+

Peer-Reviewed Publications

Contact Us

To be connected with a local representative in your area, fill out the details below:

By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.
References
Voigt J, Ikeme S. Cost analysis comparing two human allogra s in healing diabe c foot ulcers over a 16 week period. Value Health. 2019; 22: S148-S9.
Caputo WJ, Vaquero C, Monterosa A, et al. Wound Repair Regen. 2016;24(5):885-893.
Couture M. Wounds. 2016;28(7):217-25.
Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetes Care 2002; 25: 1835–9.
Fife CE, Eckert KA, Carter MJ. Adv Wound Care 2018; 7: 77–94.
Raphael A. J Wound Care. 2016;25(Sup7):S10-17.
Raphael A, Gonzales J. J Wound Care. 2017;26(Sup10):S38-44.